Clinical trials: Myeloid
Leukemia
Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about cancer and development of drug resistance in patients.
- Trial name
- NCT01419496
- Testing
- protein expression analysis, flow cytometry, laboratory biomarker analysis
- Volunteers
- 40 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. This study focuses on two types of cancers: Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer, Cancer
- Trial name
- NCT04272203
- Testing
- ABBV-184
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- AbbVie
FLT3-ITD Mutation, AML
Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD
Patients with refractory or relapsed acute myeloid leukemia (AML) after two courses of standard chemotherapy regimens have very limited options.
- Trial name
- NCT03622541
- Testing
- Sorafenib 200mg
- Where
- Hong Kong
- Volunteers
- 46 people
- Sponsor
- The University of Hong Kong
Leukemia
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in…
- Trial name
- NCT00723203
- Testing
- panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
CD34+ Transplants for Myeloid Malignancies
This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy…
- Trial name
- NCT05565105
- Testing
- Busulfan, Melphalan, Fludarabine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Guenther Koehne
Chronic Myeloproliferative Disorders, Leukemia
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00290641
- Testing
- filgrastim, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphoma
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation.
- Conditions
- Leukemia, Lymphoma, Oral Complications
- Trial name
- NCT00004061
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed or Refractory Acute Myeloid Leukemia
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
Recent preclinical and retrospective clinical data have suggested that dexamethasone might sensitize leukemic cells to chemotherapy-induced cell death and thus limit the risk of leukemic regrowth and relapse.
- Trial name
- DEXAML-03 (NCT03765541)
- Testing
- Dexamethasone, Amsacrine, Cytarabine
- Where
- 10 sites in France
- Volunteers
- 73 people
- Sponsor
- University Hospital, Toulouse
Acute Myeloid Leukemia (AML)
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease
- Trial name
- NCT07023588
- Testing
- Venetoclax
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Yehui Tan
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Extension study to provide ongoing long-term treatment with ASTX727 for participants who were benefitting from ASTX727 treatment in a previous Taiho (formerly Astex)-sponsored clinical study of ASTX727 (including, but not limited…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04093570
- Testing
- ASTX727
- Where
- 47 sites in United States, Armenia and 11 more
- Volunteers
- 332 people
- Sponsor
- Taiho Oncology, Inc.
Acute Myeloid Leukemia, Adult
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
Individualized induction therapy will be applied to the non-elderly acute myeloid leukemia (AML) patients with adverse genetic risk features guided by rapid screening with fluorescence in situ hybridization (FISH) and…
- Trial name
- NCT04752527
- Testing
- venetoclax combined with decitabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Myeloid, Chronic
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
This study will evaluate the efficacy and safety of LBH589B in adult patients with chronic myeloid leukemia who are in accelerated phase or blast phase (blast crisis) with resistant disease following treatment with at least two…
- Trial name
- NCT00449761
- Testing
- LBH589
- Where
- 26 sites in United States, Germany
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML)
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
This study is a single-arm, open-label, dose-escalating trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of anti human CI-135 (FLT3) CAR-T Injection , and to preliminarily observe the…
- Trial name
- NCT06760260
- Testing
- Human Derived anti-CI135 CAR-T Injection
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Acute Myeloid Leukemia
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
This study will examine the safety and anti-leukemic profile of SGN-CD33A (vadastuximab talirine) in patients with relapsed chemo-resistant AML, who are given vadastuximab talirine in sequence with standard treatments before a…
- Trial name
- NCT02614560
- Testing
- Fludarabine, Melphalan, vadastuximab talirine
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- Seagen Inc.
Myelofibrosis, Chronic Myelomonocytic Leukemia
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
This multicenter, multi-arm trial evaluated the safety and efficacy of tagraxofusp, a cell division cycle protein 123 homolog-targeted therapy, in participants with either CMML or MF.
- Trial name
- NCT02268253
- Testing
- Tagraxofusp Injection
- Where
- 24 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- Stemline Therapeutics, Inc.
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
This phase II trial studies the side effects and how well liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin work in treating patients with acute myeloid leukemia that has come back (relapsed) or that does…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome
- Trial name
- NCT03672539
- Testing
- Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
The main objective of this work is to conduct a clinical study for the development and application of a vaccine with autologous dendritic cells submitted to electroporation with Wilm's tumor 1 (WT1) messenger ribonucleic acid…
- Trial name
- NCT03083054
- Testing
- Autologous dendritic cells electroporated with WT1 mRNA
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- University of Campinas, Brazil
Health Care Quality, Health Care Evaluation
A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia
Patients with chronic myeloid leukemia in imatinib induced CHR are randomized between imatinib 400 mg daily and imatinib 400 mg daily + PegIntron 30 ug weekly.
- Trial name
- NCT01227356
- Testing
- imatinib and pegylated interferon
- Where
- 3 sites in Sweden
- Volunteers
- 112 people
- Sponsor
- Uppsala University
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative…
- Conditions
- Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT06523556
- Testing
- Axatilimab, Azacitidine, Biospecimen Collection
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Uma Borate
Acute Myeloid Leukemia
High-dose Cytarabine and Survival in AML
In adults with acute myeloid leukemia, especially those < 60 years of age, high-dose cytarabine consolidation therapy has been shown to influence survival, but the appropriate dose has not been defined.
- Trial name
- NCT01034839
- Where
- Brazil
- Volunteers
- 499 people
- Sponsor
- University of Sao Paulo General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.